PMCPA Case Library

Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.

1,930
Cases
291
Companies
154
Clauses
6
Code Versions

or browse all 154 ABPI clause guides ↗

Case Library Membership

Filter by Company & ABPI Clause

Search free — but unlock advanced filters to find every case involving a specific company or clause.

Filter 1,930+ cases by any of 291 companies
Filter by any of 154 ABPI Code clauses
Filter by Code version (2016, 2019, 2021…)
Full-text keyword search across all cases
Cancel any time

Already a member? Sign in →

Case Library Membership

Best value
£249 /year Save £99

inc. VAT

£29 /month

inc. VAT · cancel any time

Unlock Full Access →

Secure payment via Stripe


Need access for your team?

Company licences available for compliance teams, medical affairs, and training programmes.

Get a team quote →

1,930 cases found

08
Mar 2026
2021 Code Angelini Pharma UK-I Clause 2 Clause 5.1 Clause 8.1 Clause 11.2 Clause 12.1 Clause 12.9 Clause 15.2

Angelini: off-label discussion at meetings, disparaging EMA comments, and portal slide compliance failures (Ontozry) | AUTH/3916/5/24

Ex-employee complaint about Ontozry meetings. Panel found off-label promotion (incl PEG administration and monotherapy advocacy), references to EMA, and multiple certification/PI/AE statement…

08
Mar 2026
2021 Code GSK Clause 25

GSK breach for unclear sponsorship disclosure on third-party conference webpages (AUTH/3915/5/24)

GSK was found in breach of Clause 25.3 twice after sponsorship of a healthcare organisation’s conference was not clearly acknowledged from the…

08
Mar 2026
2021 Code Novo Nordisk Clause 5.1 Clause 26.1 Clause 26.2

Novo Nordisk: business press interview led to public promotion of Wegovy (Clause 26) and high standards breach (Clause 5.1)

Three national newspaper business articles based on a Novo Holdings interview included positive Wegovy/SELECT trial statements. PMCPA found public advertising and unbalanced…

08
Mar 2026
2021 Code Eli Lilly Clause 3 Clause 5 Clause 15 Clause 16 Clause 26

Eli Lilly: Sponsored breast cancer editorial promoted via Facebook/Instagram ads reached the public (Clause 26) and lacked clear sponsorship at the outset

A medical publisher’s “Sponsored” Facebook ad linked to a Lilly-funded breast cancer article. The Panel found disguised promotion, inadequate disclosure, lack of…

08
Mar 2026
2021 Code GSK

AUTH/3903/5/24: Complainant v GSK (Blenrep website safety claim) – No breach

Complaint challenged a Blenrep website claim (“generally well tolerated and manageable safety profile”) as misleading/unqualified. Panel found the claim sufficiently supported and…

08
Mar 2026
2021 Code Jazz Pharmaceuticals Clause 5.1 Clause 23.2 Clause 25.3

Jazz Pharmaceuticals UK: Patient organisation materials lacked clear funding disclosure from the outset (AUTH/3921/06/24)

Jazz funded a patient organisation’s health information project, but Jazz’s involvement wasn’t clearly acknowledged from the outset on the website and wasn’t…

08
Mar 2026
2021 Code Merck Serono Clause 26

AUTH/3894/4/24: Complainant v Merck Serono — LinkedIn post by UK HCP ruled out of scope (No breach)

A UK HCP shared Merck Global meeting slides on LinkedIn. Panel initially found public promotion/PI issues, but on appeal the Appeal Board…

08
Mar 2026
2021 Code Roche Clause 25

Roche breached Clause 25.3 after BBC radio programme lacked clear sponsorship declaration from the outset (AUTH/3897/5/24)

A BBC radio programme about a Roche-sponsored eye health campaign featured partner interviews without declaring Roche’s sponsorship during the audio. PMCPA ruled…

08
Mar 2026
2021 Code GSK Clause 25.3

GSK breach for patient organisation articles: funding acknowledgement not clear from the outset (AUTH/3895/5/24)

Four patient-facing articles funded by a GSK grant disclosed the funding only at the bottom of each page. PMCPA ruled a narrow…

08
Mar 2026
2021 Code GSK Clause 25

GSK COPD decision support tool: sponsorship declaration not shown from the outset (Clause 25.3)

GSK-sponsored COPD decision support tool lacked a prominent sponsorship declaration at the outset of the homepage after sponsorship ended. PMCPA ruled a…

08
Mar 2026
2021 Code GSK

AUTH/3899/5/24: Complainant v GSK — COPD therapy review Joint Working classification and certification (No breach)

Complaint alleged a COPD therapy review service was misclassified as Joint Working and that software, patient leaflets and consultation summaries weren’t certified.…

08
Mar 2026
2024 Code Roche Products Clause 9

Roche breach over ambiguous sponsorship disclosure on university white paper webpage (AUTH/3924/6/24)

PMCPA ruled Roche breached Clause 9.10 (2016) because a university webpage described Roche only as “Client”, an ambiguous disclosure. The white paper…

08
Mar 2026
2021 Code AstraZeneca Clause 26

AstraZeneca corporate medicines webpage: inaccurate black triangle status breached Clause 26.2

A clinician complained that AstraZeneca’s public corporate medicines list showed incorrect/missing black triangle symbols and omitted Imjudo. The Panel found a breach…

08
Mar 2026
2021 Code GSK UK

AUTH/3923/6/24: Complainant v GSK — Trelegy sales aid alleged off-label promotion (No breach)

Anonymous health professional alleged GSK sales aids promoted Trelegy for patients inadequately treated on multiple-inhaler triple therapy (MITT). Panel ruled no breach…

08
Mar 2026
2021 Code GSK UK

AUTH/3922/6/24: Complainant v GSK — Trelegy banner alleged off-label switch claim (No breach)

Complaint alleged a Trelegy Ellipta rotating banner promoted an unlicensed switch from three inhalers (incl. SABA). PMCPA Panel found no breach of…

1234129

Ask questions about any PMCPA case

Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free